RhPDCD5 combined with dexamethasone increases antitumor activity in multiple myeloma partially via inhibiting the Wnt signalling pathway

Publisher： John Wiley & Sons Inc

E-ISSN： 1440-1681|45|2|140-145

ISSN： 0305-1870

Source： CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol.45, Iss.2, 2018-02, pp. : 140-145

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 754-756

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 3, 2015-11 ,pp. : 344-354

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sophocarpine attenuates wear particle‐induced implant loosening by inhibiting osteoclastogenesis and bone resorption via suppression of the NF‐κB signalling pathway in a rat model

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 175, Iss. 6, 2018-03 ,pp. : 859-876

John Wiley & Sons Inc

Access to resources Recommend Favorite

SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway

By  

THE JOURNAL OF PATHOLOGY, Vol. 235, Iss. 4, 2015-03 ,pp. : 559-570

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway

By                

International Journal of Molecular Medicine, Vol. 30, Iss. 2, 2012-01 ,pp. : 337-343

Spandidos Publications

Access to resources Recommend Favorite